mRNA Cancer Drug Shows Positive Results in Major Trial
The story in brief
Moderna and Merck announced positive results from a large, late-stage trial for the mRNA-based drug intismeran autogene, which targets melanoma by analyzing a patient's tumor. The breakthrough, the first of its kind for an mRNA cancer drug, sent Moderna's stock up 145% and Merck's up 12%. The treatment uses mRNA technology similar to that in Covid-19 vaccines, offering personalized cancer therapy.